Drug Profile
Ethyl eicosapentaenoic acid/niacin - Amarin
Latest Information Update: 21 Sep 2011
Price :
$50
*
At a glance
- Originator Amarin Corporation
- Class
- Mechanism of Action GPR109A receptor agonists; Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 29 Nov 2007 Phase-I clinical trials in Hyperlipidaemia in United Kingdom (PO)